Illumina continues to focus on transforming human health practices through its leadership in genomic sequencing and related applications. The company offers a wide range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be broad, such as population genomics initiatives in many countries, or narrow, such as non-invasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and certain acquisitions.